Covered recipient · General Payments record
CRAIG FORREST TELLER
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$243,515.15
330 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $156,162.25 | 58 |
| Consulting Fee | $45,710.00 | 8 |
| Travel and Lodging | $29,242.61 | 82 |
| Food and Beverage | $7,521.01 | 177 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,400.00 | 1 |
| Honoraria | $2,300.00 | 1 |
| Education | $179.28 | 3 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie, Inc. | $54,022.07 | 72 |
| Allergan Inc. | $53,519.65 | 64 |
| Regeneron Healthcare Solutions, Inc. | $28,731.14 | 28 |
| Janssen Scientific Affairs, LLC | $19,702.28 | 16 |
| Lilly USA, LLC | $18,609.75 | 22 |
| GENZYME CORPORATION | $15,235.39 | 22 |
| Celgene Corporation | $11,467.42 | 14 |
| Novartis Pharmaceuticals Corporation | $10,023.20 | 22 |
| Amgen Inc. | $9,163.16 | 8 |
| Genentech USA, Inc. | $6,829.12 | 4 |
| Janssen Biotech, Inc. | $5,857.68 | 15 |
| TARO PHARMACEUTICALS USA, INC. | $2,615.63 | 2 |
| Almirall LLC | $2,592.25 | 5 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $2,512.88 | 3 |
| LEO Pharma Inc. | $1,050.00 | 1 |
| Galderma Laboratories, L.P. | $646.02 | 16 |
| Merz North America, Inc. | $577.26 | 6 |
| PFIZER INC. | $104.79 | 3 |
| Regeneron Pharmaceuticals, Inc. | $86.58 | 1 |
| SANOFI-AVENTIS U.S. LLC | $72.00 | 1 |
| Biofrontera Inc. | $53.20 | 2 |
| Mayne Pharma Inc. | $26.48 | 2 |
| Helsinn Therapeutics (U.S.), Inc. | $17.20 | 1 |
Page 7 of 7; records 301–330 of 330 matching records. This page contains 30 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CRAIG FORREST TELLER
NPI 1851351357 · CMS profile ID 219600
Allopathic & Osteopathic Physicians / Dermatology
BELLAIRE, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 7 of 7; records 301–330 of 330 matching records. This page contains 30 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1851351357?year=2019&recipient=provider&page=7#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CRAIG FORREST TELLER, NPI 1851351357, CMS profile ID 219600. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 7; records 301–330 of 330 matching records. This page contains 30 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851351357?year=2019&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). CRAIG FORREST TELLER, NPI 1851351357, CMS profile ID 219600. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 7; records 301–330 of 330 matching records. This page contains 30 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851351357?year=2019&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- CRAIG FORREST TELLER, NPI 1851351357, CMS profile ID 219600, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 7 of 7; records 301–330 of 330 matching records. This page contains 30 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1851351357?year=2019&recipient=provider&page=7#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
330 matching records · $243,515.15 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 301–330 of 330.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $2,450.00 | 01/16/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657755843 | CMS |
| Novartis Pharmaceuticals Corporation | $46.60 | 01/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660008187 | CMS |
| Allergan Inc. | $17.52 | 01/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671220569 | CMS |
| Allergan Inc. | $15.95 | 01/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671220571 | CMS |
| Celgene Corporation | $38.92 | 01/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672837131 | CMS |
| Celgene Corporation | $33.93 | 01/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672844350 | CMS |
| Celgene Corporation | $200.80 | 01/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672844356 | CMS |
| Celgene Corporation | $40.00 | 01/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672848655 | CMS |
| Celgene Corporation | $56.37 | 01/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672848711 | CMS |
| Celgene Corporation | $336.98 | 01/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672850639 | CMS |
| Celgene Corporation | $6,280.00 | 01/12/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672857417 | CMS |
| Celgene Corporation | $56.66 | 01/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672863831 | CMS |
| Celgene Corporation | $224.88 | 01/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673014319 | CMS |
| Lilly USA, LLC | $16.92 | 01/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657735037 | CMS |
| AbbVie, Inc. | $27.00 | 01/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647812311 | CMS |
| Lilly USA, LLC | $50.10 | 01/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657731559 | CMS |
| Lilly USA, LLC | $741.74 | 01/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657731561 | CMS |
| Lilly USA, LLC | $168.88 | 01/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657738475 | CMS |
| Lilly USA, LLC | $329.94 | 01/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657738477 | CMS |
| Lilly USA, LLC | $95.90 | 01/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657741957 | CMS |
| Lilly USA, LLC | $77.81 | 01/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657731563 | CMS |
| Lilly USA, LLC | $802.08 | 01/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657735033 | CMS |
| Lilly USA, LLC | $21.20 | 01/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657735035 | CMS |
| Lilly USA, LLC | $0.98 | 01/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657738479 | CMS |
| AbbVie, Inc. | $19.16 | 01/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647812185 | CMS |
| Almirall LLC | $134.08 | 01/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676672413 | CMS |
| Almirall LLC | $549.41 | 01/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676672409 | CMS |
| Almirall LLC | $258.77 | 01/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676672411 | CMS |
| Almirall LLC | $149.99 | 01/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676672417 | CMS |
| Novartis Pharmaceuticals Corporation | $14.38 | 01/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660008167 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,097,707.89 | 543 |
| PY2024 | Recipient | $507.43 | 3 |
| PY2024 | Principal investigator | $1,401,159.23 | 581 |
| PY2023 | Principal investigator | $619,404.95 | 202 |
| PY2022 | Principal investigator | $922,540.73 | 143 |
| PY2021 | Recipient | $11,400.00 | 1 |
| PY2021 | Principal investigator | $752,004.96 | 125 |
| PY2020 | Recipient | $6,722.74 | 3 |
| PY2020 | Principal investigator | $753,353.67 | 159 |
| PY2019 | Recipient | $5,372.41 | 6 |
| PY2019 | Principal investigator | $821,486.03 | 104 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
543 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $8,420.82 | 12/31/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY | A Prospective, Open-Label Study to Evaluate Subject Satisfaction with Overall Facial Appearance After Treatment with JUVeDERM Products in Medical Weight Loss (MWL) Subjects | No dispute reported | 06/30/2026 | 1202534109 |
| Principal investigator 1 | ABBVIE INC. | $1,529.40 | 12/31/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata | No dispute reported | 06/30/2026 | 1202534131 |
| Principal investigator 1 | ABBVIE INC. | $10,083.36 | 12/31/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202534133 |
| Principal investigator 1 | ABBVIE INC. | $3,537.36 | 12/31/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy | No dispute reported | 06/30/2026 | 1202534135 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $500.00 | 12/24/2025 | Non-covered Recipient Entity Bellaire Dermatology Associates | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430908 |
| Principal investigator 1 | ABBVIE INC. | $1,076.00 | 12/22/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202531638 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,837.83 | 12/17/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190302251 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,487.50 | 12/12/2025 | Non-covered Recipient Entity Bellaire Dermatology Associates | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430906 |
| Principal investigator 1 | Incyte Corporation | $531.50 | 12/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240507247 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 12/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507273 |
| Principal investigator 1 | Incyte Corporation | $1,139.40 | 12/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507307 |
| Principal investigator 1 | Incyte Corporation | $1,899.00 | 12/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507312 |
| Principal investigator 1 | Incyte Corporation | $1,899.00 | 12/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507316 |
| Principal investigator 1 | Incyte Corporation | $1,899.00 | 12/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507320 |
| Principal investigator 1 | Incyte Corporation | $11,810.30 | 12/08/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507299 |
| Principal investigator 1 | ABBVIE INC. | $2,688.40 | 12/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202526580 |
| Principal investigator 1 | ABBVIE INC. | $15,729.70 | 12/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202526808 |
| Principal investigator 1 | ABBVIE INC. | $4,227.50 | 12/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202526810 |
| Principal investigator 1 | ABBVIE INC. | $1,568.10 | 12/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202527464 |
| Principal investigator 1 | ABBVIE INC. | $3,270.20 | 12/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202527470 |
| Principal investigator 1 | ABBVIE INC. | $2,608.60 | 12/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202527482 |
| Principal investigator 1 | Incyte Corporation | $1,169.30 | 12/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240507243 |
| Principal investigator 1 | Incyte Corporation | $9.48 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507337 |
| Principal investigator 1 | Incyte Corporation | $20.40 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507342 |
| Principal investigator 1 | Incyte Corporation | $30.81 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507346 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507351 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507356 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507361 |
| Principal investigator 1 | Incyte Corporation | $52.14 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507364 |
| Principal investigator 1 | Incyte Corporation | $33.18 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507368 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507388 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507393 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507398 |
| Principal investigator 1 | Incyte Corporation | $11.85 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507415 |
| Principal investigator 1 | Incyte Corporation | $11.85 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507419 |
| Principal investigator 1 | Incyte Corporation | $47.40 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507452 |
| Principal investigator 1 | Incyte Corporation | $47.40 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507456 |
| Principal investigator 1 | Incyte Corporation | $14.22 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507461 |
| Principal investigator 1 | Incyte Corporation | $23.70 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507483 |
| Principal investigator 1 | Incyte Corporation | $23.70 | 12/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507487 |
| Principal investigator 1 | ABBVIE INC. | $2,683.20 | 11/26/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202525534 |
| Principal investigator 1 | ABBVIE INC. | $708.50 | 11/26/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202525536 |
| Principal investigator 1 | ABBVIE INC. | $1,508.00 | 11/26/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202525562 |
| Principal investigator 1 | Incyte Corporation | $956.70 | 11/25/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240507235 |
| Principal investigator 1 | Incyte Corporation | $825.00 | 11/24/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507295 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 11/24/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507325 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 11/24/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507328 |
| Principal investigator 1 | Incyte Corporation | $356.00 | 11/24/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507444 |
| Principal investigator 1 | Incyte Corporation | $395.40 | 11/24/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507472 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 11/24/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507491 |
| Principal investigator 1 | Incyte Corporation | $320.00 | 11/19/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507372 |
| Principal investigator 1 | Incyte Corporation | $956.70 | 11/16/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240507238 |
| Principal investigator 1 | ABBVIE INC. | $1,698.00 | 11/13/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) | No dispute reported | 06/30/2026 | 1202524185 |
| Principal investigator 1 | Incyte Corporation | $450.00 | 11/12/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507423 |
| Principal investigator 1 | Incyte Corporation | $1,320.00 | 11/12/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507448 |
| Principal investigator 1 | ABBVIE INC. | $7,647.60 | 11/11/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) | No dispute reported | 06/30/2026 | 1202523763 |
| Principal investigator 1 | Incyte Corporation | $1,899.00 | 11/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507401 |
| Principal investigator 1 | Incyte Corporation | $1,899.00 | 11/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507405 |
| Principal investigator 1 | Incyte Corporation | $677.00 | 11/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507500 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 11/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507504 |
| Principal investigator 1 | ABBVIE INC. | $349.38 | 11/05/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202522395 |
| Principal investigator 1 | ABBVIE INC. | $15,475.20 | 11/05/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202522397 |
| Principal investigator 1 | ABBVIE INC. | $9,390.80 | 11/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202520659 |
| Principal investigator 1 | Incyte Corporation | $137.40 | 11/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507277 |
| Principal investigator 1 | Incyte Corporation | $369.00 | 11/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507281 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 11/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507333 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 11/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507428 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 11/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507432 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 11/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507436 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 11/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507440 |
| Principal investigator 1 | Incyte Corporation | $4.24 | 11/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507496 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,747.20 | 10/22/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287329 |
| Principal investigator 1 | Incyte Corporation | $629.70 | 10/20/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507376 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 10/20/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507381 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 10/20/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507384 |
| Principal investigator 1 | Incyte Corporation | $348.00 | 10/20/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507476 |
| Principal investigator 1 | Incyte Corporation | $2,063.00 | 10/20/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507479 |
| Principal investigator 1 | ABBVIE INC. | $984.00 | 10/16/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) | No dispute reported | 06/30/2026 | 1202517253 |
| Principal investigator 1 | Eli Lilly and Company | $5,894.00 | 10/14/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187877043 |
| Principal investigator 1 | ABBVIE INC. | $1,820.30 | 10/09/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202515113 |
| Principal investigator 1 | ABBVIE INC. | $759.30 | 10/09/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202515115 |
| Principal investigator 1 | ABBVIE INC. | $9,178.50 | 10/09/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202515117 |
| Principal investigator 1 | ABBVIE INC. | $2,168.00 | 10/09/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202515285 |
| Principal investigator 1 | ABBVIE INC. | $1,293.80 | 10/09/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202515287 |
| Principal investigator 1 | ABBVIE INC. | $1,325.60 | 10/09/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202515289 |
| Principal investigator 1 | Incyte Corporation | $660.50 | 10/08/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507251 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 10/08/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507255 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 10/08/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507260 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 10/08/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507264 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 10/08/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507269 |
| Principal investigator 1 | Incyte Corporation | $1,709.10 | 10/08/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507304 |
| Principal investigator 1 | Incyte Corporation | $2,063.00 | 10/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507286 |
| Principal investigator 1 | Incyte Corporation | $2,063.00 | 10/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507290 |
| Principal investigator 1 | Incyte Corporation | $2,063.00 | 10/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507293 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 10/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507410 |
| Principal investigator 1 | Incyte Corporation | $241.50 | 10/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507464 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 10/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507468 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505825 |
| Principal investigator 1 | Incyte Corporation | $14.84 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505829 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505833 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505839 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505842 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505846 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505850 |
| Principal investigator 1 | Incyte Corporation | $12.72 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505853 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505859 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505862 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505866 |
| Principal investigator 1 | Incyte Corporation | $57.25 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505869 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505873 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505877 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505880 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505885 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505888 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505893 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505897 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505900 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505904 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505907 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505912 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505916 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,500.00 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY | A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1190302249 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,474.90 | 10/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286131 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,615.63 | 09/26/2025 | Non-covered Recipient Entity Bellaire Dermatology Associates | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430904 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 09/23/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240506921 |
| Principal investigator 1 | Incyte Corporation | $956.70 | 09/23/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240506930 |
| Principal investigator 1 | Incyte Corporation | $3,000.00 | 09/23/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240506933 |
| Principal investigator 1 | ABBVIE INC. | $150.00 | 09/19/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) | No dispute reported | 06/30/2026 | 1202511638 |
| Principal investigator 1 | Incyte Corporation | $956.70 | 09/18/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240506917 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $66,185.92 | 09/11/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S | No dispute reported | 06/30/2026 | 1190302255 |
| Principal investigator 1 | Incyte Corporation | $660.50 | 09/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507109 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 09/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507113 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 09/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507117 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 09/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507123 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 09/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507127 |
| Principal investigator 1 | ABBVIE INC. | $6,021.90 | 09/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202508870 |
| Principal investigator 1 | ABBVIE INC. | $1,244.40 | 09/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202509662 |
| Principal investigator 1 | ABBVIE INC. | $5,732.40 | 09/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) | No dispute reported | 06/30/2026 | 1202509664 |
| Principal investigator 1 | Incyte Corporation | $2,870.10 | 09/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240506926 |
| Principal investigator 1 | ABBVIE INC. | $4,784.90 | 09/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202508266 |
| Principal investigator 1 | ABBVIE INC. | $9,353.60 | 09/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202508270 |
| Principal investigator 1 | ABBVIE INC. | $11,830.80 | 09/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202508272 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,977.00 | 09/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284909 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506994 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506998 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507001 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507006 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507010 |
| Principal investigator 1 | Incyte Corporation | $10.60 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507014 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507019 |
| Principal investigator 1 | Incyte Corporation | $4.24 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507022 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507027 |
| Principal investigator 1 | Incyte Corporation | $14.58 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507031 |
| Principal investigator 1 | Incyte Corporation | $9.72 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507037 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507041 |
| Principal investigator 1 | Incyte Corporation | $98.72 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507045 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507049 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507052 |
| Principal investigator 1 | Incyte Corporation | $0.93 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507056 |
| Principal investigator 1 | Incyte Corporation | $0.31 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507060 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507065 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507084 |
| Principal investigator 1 | Incyte Corporation | $4.86 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507131 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507135 |
| Principal investigator 1 | Incyte Corporation | $34.35 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507138 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507142 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507148 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507152 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507157 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507179 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507184 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507188 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507196 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507212 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507216 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507221 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507226 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507231 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,000.00 | 09/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190302253 |
| Principal investigator 1 | ABBVIE INC. | $1,440.00 | 08/21/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202505329 |
| Principal investigator 1 | ABBVIE INC. | $429.00 | 08/21/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202505331 |
| Principal investigator 1 | ABBVIE INC. | $3,372.00 | 08/21/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202505333 |
| Principal investigator 1 | ABBVIE INC. | $3,321.00 | 08/21/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202505457 |
| Principal investigator 1 | ABBVIE INC. | $3,302.00 | 08/21/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202505459 |
| Principal investigator 1 | ABBVIE INC. | $3,302.00 | 08/21/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202505471 |
| Principal investigator 1 | ABBVIE INC. | $650.50 | 08/21/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202505473 |
| Principal investigator 1 | Incyte Corporation | $348.00 | 08/20/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506937 |
| Principal investigator 1 | Incyte Corporation | $858.80 | 08/20/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506941 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 08/20/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506945 |
| Principal investigator 1 | Incyte Corporation | $2,063.00 | 08/20/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506953 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 08/20/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507097 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 08/20/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507101 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 08/20/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507105 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 08/20/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507200 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 08/20/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507205 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,065.00 | 08/20/2025 | Non-covered Recipient Entity Bellaire Dermatology Associates | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430902 |
| Principal investigator 1 | ABBVIE INC. | $778.70 | 08/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202503059 |
| Principal investigator 1 | ABBVIE INC. | $5,287.20 | 08/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) | No dispute reported | 06/30/2026 | 1202503071 |
| Principal investigator 1 | ABBVIE INC. | $27,056.40 | 08/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202503077 |
| Principal investigator 1 | ABBVIE INC. | $1,890.50 | 08/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202503191 |
| Principal investigator 1 | ABBVIE INC. | $1,321.00 | 08/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202503193 |
| Principal investigator 1 | ABBVIE INC. | $4,055.60 | 08/05/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202501158 |
| Principal investigator 1 | ABBVIE INC. | $1,299.00 | 08/05/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202501160 |
| Principal investigator 1 | ABBVIE INC. | $13,337.60 | 08/05/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202501860 |
| Principal investigator 1 | ABBVIE INC. | $15,201.30 | 08/05/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202501862 |
| Principal investigator 1 | Incyte Corporation | $924.70 | 08/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506963 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 08/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506967 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 08/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506983 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 08/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507068 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 08/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507073 |
| Principal investigator 1 | Incyte Corporation | $0.62 | 08/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507076 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 08/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507080 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 08/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507089 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 08/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507093 |
| Principal investigator 1 | Incyte Corporation | $1,387.10 | 08/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506975 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 08/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506990 |
| Principal investigator 1 | Incyte Corporation | $1,899.00 | 08/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507192 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,865.90 | 08/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283405 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,401.40 | 08/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283407 |
| Principal investigator 1 | Eli Lilly and Company | $2,766.00 | 07/22/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187876005 |
| Principal investigator 1 | Eli Lilly and Company | $1,500.00 | 07/22/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187877787 |
| Principal investigator 1 | Incyte Corporation | $1,403.60 | 07/18/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506971 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 07/18/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506979 |
| Principal investigator 1 | Incyte Corporation | $1,939.00 | 07/18/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506987 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 07/18/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507160 |
| Principal investigator 1 | Incyte Corporation | $260.00 | 07/11/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507209 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 07/11/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223282590 |
| Principal investigator 1 | Incyte Corporation | $660.50 | 07/09/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506949 |
| Principal investigator 1 | Incyte Corporation | $164.00 | 07/09/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506956 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 07/09/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506959 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 07/09/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507163 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 07/09/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507167 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 07/09/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507172 |
| Principal investigator 1 | Incyte Corporation | $1,188.90 | 07/09/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240507176 |
| Principal investigator 1 | ABBVIE INC. | $1,293.80 | 07/08/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202497194 |
| Principal investigator 1 | ABBVIE INC. | $11,652.00 | 07/08/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) | No dispute reported | 06/30/2026 | 1202497332 |
| Principal investigator 1 | ABBVIE INC. | $6,709.60 | 07/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202495789 |
| Principal investigator 1 | ABBVIE INC. | $8,129.10 | 07/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202495797 |
| Principal investigator 1 | ABBVIE INC. | $5,577.60 | 07/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) | No dispute reported | 06/30/2026 | 1202495817 |
| Principal investigator 1 | ABBVIE INC. | $1,746.20 | 07/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202495825 |
| Principal investigator 1 | ABBVIE INC. | $6,087.00 | 07/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202496277 |
| Principal investigator 1 | ABBVIE INC. | $1,556.00 | 07/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202493821 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $264.00 | 07/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190304603 |
| Principal investigator 1 | ABBVIE INC. | $17,042.40 | 06/26/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) | No dispute reported | 06/30/2026 | 1202493249 |
| Principal investigator 1 | Incyte Corporation | $824.90 | 06/25/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506564 |
| Principal investigator 1 | Incyte Corporation | $348.00 | 06/25/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506583 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 06/25/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506587 |
| Principal investigator 1 | Incyte Corporation | $1,939.00 | 06/25/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506591 |
| Principal investigator 1 | Incyte Corporation | $1,939.00 | 06/25/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506595 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 06/25/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506602 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 06/25/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506875 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 06/25/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506880 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 06/23/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506611 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,520.35 | 06/20/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223281720 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,896.88 | 06/18/2025 | Non-covered Recipient Entity Bellaire Dermatology Associates | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430900 |
| Principal investigator 1 | Incyte Corporation | $520.00 | 06/13/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506599 |
| Principal investigator 1 | Incyte Corporation | $375.00 | 06/13/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506607 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,649.70 | 06/13/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223281268 |
| Principal investigator 1 | Incyte Corporation | $1,444.90 | 06/11/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506615 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 06/11/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506619 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 06/11/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506913 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 06/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506627 |
| Principal investigator 1 | Incyte Corporation | $792.60 | 06/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506883 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 06/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506888 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 06/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506892 |
| Principal investigator 1 | Janssen Research & Development, LLC | $156.00 | 06/04/2025 | Non-covered Recipient Entity Bellaire Derm | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175277807 |
| Principal investigator 1 | Janssen Research & Development, LLC | $201.00 | 06/04/2025 | Non-covered Recipient Entity Bellaire Derm | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175277901 |
| Principal investigator 1 | ABBVIE INC. | $1,700.70 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202488413 |
| Principal investigator 1 | ABBVIE INC. | $6,230.50 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202488465 |
| Principal investigator 1 | ABBVIE INC. | $10,270.80 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) | No dispute reported | 06/30/2026 | 1202488559 |
| Principal investigator 1 | ABBVIE INC. | $6,791.20 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202488677 |
| Principal investigator 1 | ABBVIE INC. | $5,265.00 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202488781 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506708 |
| Principal investigator 1 | Incyte Corporation | $80.15 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506712 |
| Principal investigator 1 | Incyte Corporation | $123.40 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506715 |
| Principal investigator 1 | Incyte Corporation | $11.45 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506719 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506723 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506727 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506731 |
| Principal investigator 1 | Incyte Corporation | $14.58 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506735 |
| Principal investigator 1 | Incyte Corporation | $10.60 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506739 |
| Principal investigator 1 | Incyte Corporation | $0.93 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506743 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506749 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506756 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506760 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506764 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506768 |
| Principal investigator 1 | Incyte Corporation | $60.77 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506814 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506903 |
| Principal investigator 1 | Incyte Corporation | $38.11 | 06/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506908 |
| Principal investigator 1 | Janssen Research & Development, LLC | $180.00 | 06/02/2025 | Non-covered Recipient Entity Bellaire Derm | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175277886 |
| Principal investigator 1 | Incyte Corporation | $2,063.00 | 05/21/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506555 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 05/21/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506559 |
| Principal investigator 1 | Incyte Corporation | $788.90 | 05/21/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506865 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,441.40 | 05/14/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223279790 |
| Principal investigator 1 | ABBVIE INC. | $6,084.00 | 05/08/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) | No dispute reported | 06/30/2026 | 1202484383 |
| Principal investigator 1 | ABBVIE INC. | $4,428.70 | 05/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202482977 |
| Principal investigator 1 | ABBVIE INC. | $9,286.20 | 05/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202482979 |
| Principal investigator 1 | ABBVIE INC. | $6,276.30 | 05/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202482981 |
| Principal investigator 1 | ABBVIE INC. | $22,571.10 | 05/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) | No dispute reported | 06/30/2026 | 1202482983 |
| Principal investigator 1 | Incyte Corporation | $727.50 | 05/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506818 |
| Principal investigator 1 | Incyte Corporation | $1,455.00 | 05/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506822 |
| Principal investigator 1 | Incyte Corporation | $1,455.00 | 05/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506827 |
| Principal investigator 1 | Incyte Corporation | $1,455.00 | 05/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506831 |
| Principal investigator 1 | Incyte Corporation | $1,455.00 | 05/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506835 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,558.50 | 05/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223279152 |
| Principal investigator 1 | ABBVIE INC. | $11,131.60 | 05/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202481587 |
| Principal investigator 1 | ABBVIE INC. | $2,387.40 | 05/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202481589 |
| Principal investigator 1 | Incyte Corporation | $1,939.00 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506521 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506524 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506530 |
| Principal investigator 1 | Incyte Corporation | $792.60 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506569 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506573 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506578 |
| Principal investigator 1 | Incyte Corporation | $65.76 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506635 |
| Principal investigator 1 | Incyte Corporation | $311.35 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506639 |
| Principal investigator 1 | Incyte Corporation | $677.00 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506641 |
| Principal investigator 1 | Incyte Corporation | $19.08 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506645 |
| Principal investigator 1 | Incyte Corporation | $194.65 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506650 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506659 |
| Principal investigator 1 | Incyte Corporation | $148.08 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506663 |
| Principal investigator 1 | Incyte Corporation | $295.65 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506772 |
| Principal investigator 1 | Incyte Corporation | $65.76 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506803 |
| Principal investigator 1 | Incyte Corporation | $65.76 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506807 |
| Principal investigator 1 | Incyte Corporation | $65.76 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506810 |
| Principal investigator 1 | Incyte Corporation | $859.70 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506839 |
| Principal investigator 1 | Incyte Corporation | $1,939.00 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506843 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506852 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506857 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 05/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506861 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,310.00 | 04/28/2025 | Non-covered Recipient Entity Bellaire Derm | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175277623 |
| Principal investigator 1 | ABBVIE INC. | $672.00 | 04/16/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202476917 |
| Principal investigator 1 | ABBVIE INC. | $3,843.90 | 04/16/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202476926 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,994.60 | 04/16/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223278116 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,555.00 | 04/11/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277958 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,257.10 | 04/11/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278056 |
| Principal investigator 1 | ABBVIE INC. | $873.60 | 04/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202475696 |
| Principal investigator 1 | ABBVIE INC. | $226.20 | 04/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202475700 |
| Principal investigator 1 | ABBVIE INC. | $741.00 | 04/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202475727 |
| Principal investigator 1 | Incyte Corporation | $1,188.90 | 04/09/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506534 |
| Principal investigator 1 | Incyte Corporation | $1,455.00 | 04/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506538 |
| Principal investigator 1 | Incyte Corporation | $979.30 | 04/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506543 |
| Principal investigator 1 | Incyte Corporation | $1,406.00 | 04/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506900 |
| Principal investigator 1 | ABBVIE INC. | $3,596.70 | 04/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202470467 |
| Principal investigator 1 | ABBVIE INC. | $9,381.60 | 04/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) | No dispute reported | 06/30/2026 | 1202470650 |
| Principal investigator 1 | ABBVIE INC. | $1,421.20 | 04/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202470655 |
| Principal investigator 1 | ABBVIE INC. | $349.38 | 04/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202470816 |
| Principal investigator 1 | ABBVIE INC. | $1,341.90 | 04/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202470821 |
| Principal investigator 1 | ABBVIE INC. | $12,240.00 | 04/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202470827 |
| Principal investigator 1 | ABBVIE INC. | $8,317.20 | 04/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202471208 |
| Principal investigator 1 | Incyte Corporation | $850.00 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506541 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506547 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506551 |
| Principal investigator 1 | Incyte Corporation | $22.66 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506623 |
| Principal investigator 1 | Incyte Corporation | $8.48 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506631 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506655 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506667 |
| Principal investigator 1 | Incyte Corporation | $37.66 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506672 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506677 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506681 |
| Principal investigator 1 | Incyte Corporation | $153.70 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506684 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506687 |
| Principal investigator 1 | Incyte Corporation | $121.90 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506692 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506696 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506699 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506703 |
| Principal investigator 1 | Incyte Corporation | $190.80 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506776 |
| Principal investigator 1 | Incyte Corporation | $49.44 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506780 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506785 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506789 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506794 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506797 |
| Principal investigator 1 | Incyte Corporation | $37.66 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506848 |
| Principal investigator 1 | Incyte Corporation | $249.10 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506869 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506872 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 04/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506896 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,800.00 | 04/02/2025 | Non-covered Recipient Entity Bellaire Dermatology Associates Pa | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults | No dispute reported | 06/30/2026 | 1226086551 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,310.00 | 03/24/2025 | Non-covered Recipient Entity Bellaire Derm Assoc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175277854 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,768.75 | 03/24/2025 | Non-covered Recipient Entity Bellaire Dermatology Associates | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246430898 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,961.75 | 03/14/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223276727 |
| Principal investigator 1 | Incyte Corporation | $924.70 | 03/12/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506074 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 03/12/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506078 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 03/12/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506083 |
| Principal investigator 1 | Incyte Corporation | $304.00 | 03/12/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506087 |
| Principal investigator 1 | Incyte Corporation | $1,444.00 | 03/12/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506091 |
| Principal investigator 1 | Incyte Corporation | $1,406.00 | 03/12/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506415 |
| Principal investigator 1 | Incyte Corporation | $1,406.00 | 03/12/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506418 |
| Principal investigator 1 | Incyte Corporation | $1,406.00 | 03/12/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506423 |
| Principal investigator 1 | Incyte Corporation | $1,406.00 | 03/12/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506427 |
| Principal investigator 1 | Incyte Corporation | $1,444.00 | 03/12/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506511 |
| Principal investigator 1 | Incyte Corporation | $1,444.00 | 03/12/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506516 |
| Principal investigator 1 | ABBVIE INC. | $2,538.20 | 03/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202459554 |
| Principal investigator 1 | ABBVIE INC. | $10,085.70 | 03/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202459760 |
| Principal investigator 1 | ABBVIE INC. | $10,192.80 | 03/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202459764 |
| Principal investigator 1 | ABBVIE INC. | $3,183.00 | 03/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202459767 |
| Principal investigator 1 | ABBVIE INC. | $102.00 | 03/07/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202459821 |
| Principal investigator 1 | ABBVIE INC. | $1,120.90 | 03/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202456687 |
| Principal investigator 1 | ABBVIE INC. | $7,036.00 | 03/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202456764 |
| Principal investigator 1 | Eli Lilly and Company | $68,227.00 | 03/04/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187874845 |
| Principal investigator 1 | Incyte Corporation | $1,354.00 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505966 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506096 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506100 |
| Principal investigator 1 | Incyte Corporation | $1,939.00 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506108 |
| Principal investigator 1 | Incyte Corporation | $908.40 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506112 |
| Principal investigator 1 | Incyte Corporation | $547.60 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506260 |
| Principal investigator 1 | Incyte Corporation | $591.30 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506264 |
| Principal investigator 1 | Incyte Corporation | $273.80 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506268 |
| Principal investigator 1 | Incyte Corporation | $148.08 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506271 |
| Principal investigator 1 | Incyte Corporation | $172.76 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506276 |
| Principal investigator 1 | Incyte Corporation | $97.08 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506280 |
| Principal investigator 1 | Incyte Corporation | $97.08 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506283 |
| Principal investigator 1 | Incyte Corporation | $591.30 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506287 |
| Principal investigator 1 | Incyte Corporation | $1,354.00 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506291 |
| Principal investigator 1 | Incyte Corporation | $240.45 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506295 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506298 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506300 |
| Principal investigator 1 | Incyte Corporation | $46.17 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506306 |
| Principal investigator 1 | Incyte Corporation | $29.16 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506310 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506314 |
| Principal investigator 1 | Incyte Corporation | $12.15 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506318 |
| Principal investigator 1 | Incyte Corporation | $3.10 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506321 |
| Principal investigator 1 | Incyte Corporation | $622.70 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506326 |
| Principal investigator 1 | Incyte Corporation | $24.30 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506331 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506335 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506339 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506342 |
| Principal investigator 1 | Incyte Corporation | $1.86 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506347 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506366 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506370 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506376 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506487 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506490 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 03/03/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506494 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,466.00 | 02/27/2025 | Non-covered Recipient Entity Bellaire Derm Assoc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175277640 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,310.00 | 02/27/2025 | Non-covered Recipient Entity Bellaire Derm Assoc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175277656 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,466.00 | 02/27/2025 | Non-covered Recipient Entity Bellaire Derm Assoc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175277783 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,756.50 | 02/26/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275667 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 02/19/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202452525 |
| Principal investigator 1 | Incyte Corporation | $13.30 | 02/19/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505997 |
| Principal investigator 1 | Incyte Corporation | $1,444.00 | 02/19/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506001 |
| Principal investigator 1 | Incyte Corporation | $618.10 | 02/19/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506007 |
| Principal investigator 1 | Incyte Corporation | $2,078.00 | 02/19/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506010 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 02/19/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506350 |
| Principal investigator 1 | Incyte Corporation | $2,078.00 | 02/19/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506449 |
| Principal investigator 1 | Incyte Corporation | $2,078.00 | 02/19/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506457 |
| Principal investigator 1 | Incyte Corporation | $2,078.00 | 02/19/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506462 |
| Principal investigator 1 | ABBVIE INC. | $136.00 | 02/18/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M18-891 - A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 1202452337 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,890.05 | 02/12/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223275197 |
| Principal investigator 1 | Incyte Corporation | $1,175.50 | 02/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506015 |
| Principal investigator 1 | Incyte Corporation | $633.70 | 02/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506019 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 02/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506024 |
| Principal investigator 1 | Incyte Corporation | $1,455.00 | 02/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506028 |
| Principal investigator 1 | Incyte Corporation | $1,455.00 | 02/10/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506032 |
| Principal investigator 1 | ABBVIE INC. | $20,596.20 | 02/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202446959 |
| Principal investigator 1 | ABBVIE INC. | $1,236.25 | 02/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202446964 |
| Principal investigator 1 | ABBVIE INC. | $51.00 | 02/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202446967 |
| Principal investigator 1 | ABBVIE INC. | $9,235.70 | 02/06/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) | No dispute reported | 06/30/2026 | 1202447053 |
| Principal investigator 1 | ABBVIE INC. | $6,055.30 | 02/05/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202444003 |
| Principal investigator 1 | ABBVIE INC. | $15,058.40 | 02/05/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202444019 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,813.40 | 02/01/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S | No dispute reported | 06/30/2026 | 1190304605 |
| Principal investigator 1 | Amgen Inc. | $22,153.81 | 01/27/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246639591 |
| Principal investigator 1 | Eli Lilly and Company | $2,885.29 | 01/27/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187876397 |
| Principal investigator 1 | Incyte Corporation | $207.20 | 01/27/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506036 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 01/27/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506041 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 01/27/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506061 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 01/27/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506065 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 01/27/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506431 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 01/27/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506436 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 01/27/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506440 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 01/27/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506445 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,228.00 | 01/27/2025 | Non-covered Recipient Entity Bellaire Derm Assoc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175277719 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,228.00 | 01/27/2025 | Non-covered Recipient Entity Bellaire Derm Assoc | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175277932 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,305.24 | 01/17/2025 | Non-covered Recipient Entity Bellaire Dermatology | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | No dispute reported | 06/30/2026 | 1235998692 |
| Principal investigator 1 | Incyte Corporation | $1,406.00 | 01/17/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506044 |
| Principal investigator 1 | Incyte Corporation | $1,406.00 | 01/17/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506049 |
| Principal investigator 1 | Incyte Corporation | $1,406.00 | 01/17/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506053 |
| Principal investigator 1 | Incyte Corporation | $1,406.00 | 01/17/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506057 |
| Principal investigator 1 | Incyte Corporation | $2,078.00 | 01/17/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506070 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 01/17/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506395 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 01/17/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506400 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 01/17/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506404 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 01/17/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506407 |
| Principal investigator 1 | Incyte Corporation | $1,321.00 | 01/17/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506411 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,035.30 | 01/17/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATE | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223274229 |
| Principal investigator 1 | Incyte Corporation | $351.60 | 01/15/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505969 |
| Principal investigator 1 | Incyte Corporation | $348.00 | 01/15/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505974 |
| Principal investigator 1 | Incyte Corporation | $1,455.00 | 01/15/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505982 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 01/15/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240505993 |
| Principal investigator 1 | Incyte Corporation | $1,244.00 | 01/15/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506004 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 01/15/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506355 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 01/15/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506358 |
| Principal investigator 1 | Incyte Corporation | $1,348.00 | 01/15/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506362 |
| Principal investigator 1 | Incyte Corporation | $348.00 | 01/15/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506501 |
| Principal investigator 1 | Incyte Corporation | $348.00 | 01/15/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506506 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $19.88 | 01/15/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY | A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1190304601 |
| Principal investigator 1 | ABBVIE INC. | $2,842.40 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202433537 |
| Principal investigator 1 | ABBVIE INC. | $3,107.30 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202433582 |
| Principal investigator 1 | ABBVIE INC. | $537.75 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202433585 |
| Principal investigator 1 | Incyte Corporation | $265.00 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506105 |
| Principal investigator 1 | Incyte Corporation | $270.30 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506118 |
| Principal investigator 1 | Incyte Corporation | $291.50 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506122 |
| Principal investigator 1 | Incyte Corporation | $38.88 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506128 |
| Principal investigator 1 | Incyte Corporation | $90.10 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506132 |
| Principal investigator 1 | Incyte Corporation | $254.40 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506135 |
| Principal investigator 1 | Incyte Corporation | $180.20 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506140 |
| Principal investigator 1 | Incyte Corporation | $174.90 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506144 |
| Principal investigator 1 | Incyte Corporation | $53.80 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506147 |
| Principal investigator 1 | Incyte Corporation | $259.70 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506151 |
| Principal investigator 1 | Incyte Corporation | $227.90 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506157 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506162 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506168 |
| Principal investigator 1 | Incyte Corporation | $172.76 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506172 |
| Principal investigator 1 | Incyte Corporation | $114.50 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506176 |
| Principal investigator 1 | Incyte Corporation | $113.26 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506180 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506184 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506187 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506191 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506193 |
| Principal investigator 1 | Incyte Corporation | $114.50 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506199 |
| Principal investigator 1 | Incyte Corporation | $5.38 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506203 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506206 |
| Principal investigator 1 | Incyte Corporation | $10.60 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506210 |
| Principal investigator 1 | Incyte Corporation | $10.60 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506215 |
| Principal investigator 1 | Incyte Corporation | $41.31 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506219 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506223 |
| Principal investigator 1 | Incyte Corporation | $5.27 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506227 |
| Principal investigator 1 | Incyte Corporation | $2.17 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506231 |
| Principal investigator 1 | Incyte Corporation | $148.08 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506235 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506238 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506242 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506247 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506251 |
| Principal investigator 1 | Incyte Corporation | $113.26 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506255 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506380 |
| Principal investigator 1 | Incyte Corporation | $111.30 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506384 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506387 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506392 |
| Principal investigator 1 | Incyte Corporation | $5.38 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506466 |
| Principal investigator 1 | Incyte Corporation | $53.80 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506470 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506473 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506478 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506483 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity BELLAIRE DERMATOLOGY ASSOCIATES BDA | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240506497 |